Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of frexalimab versus placebo in adults with non-relapsing secondary progressive multiple sclerosis
CTR20241680Phase 3Active
- Sponsor
- Sanofi
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of frexalimab in secondary-progressive multiple sclerosis (SPMS), sponsored by Sanofi. Started Sep 2024; status: active.
02
Drugs
frexalimab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on CTR20241680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241680.